Rami Al-Hader, MD
Neurology · Washington, DCNPI 1346700341
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,455 of the $13,521 with a category attached, or 62.5%. TG Therapeutics, Inc. accounts for 85.2% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $11,012, more than ten times the $268 reported in 2023.
Across 55 payments — averaging $245.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$12K
- EMD Serono, Inc.$966
- Novartis$200
- Genentech USA, Inc.$156
- Axsome Therapeutics, Inc.$122
- Sanofi$119
- plus $438 from 6 others
What the payments were for
- Consulting fees$1,41310%
- Speaking & faculty fees$8,45563%
- Travel & lodging$7586%
- Food & beverage$2,78221%
- Education$350%
- Gifts$791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 20 | $11,521 |
| EMD Serono, Inc. | 10 | $966 |
| Novartis | 11 | $200 |
| Genentech USA, Inc. | 2 | $156 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Sanofi | 1 | $119 |
| E.r. Squibb & Sons, L.L.C. | 1 | $116 |
| Biogen | 3 | $98 |
| AstraZeneca | 3 | $72 |
| Medtronic | 1 | $71 |
| CSL Behring | 1 | $47 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,521 in reported general payments places this provider in the 75th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 21 | $862 |
| Duloxetine Hcl | 18 | $507 |
Paid to pharmacies, not to this prescriber.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.